Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (91-100 of 349) with videos related to

Pageof 35
Sort By:
Journal of the American College of Cardiology|January 21, 2017
Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular StudiesMarkus C Elze, John Gregson, Usman Baber, et al.
European Journal of Heart Failure|March 5, 2024
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysisJoão Pedro Ferreira, Faiez Zannad, Milton Packer, et al.
Cardiovascular Diabetology|April 26, 2008
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)Michel Komajda, Paula Curtis, Markolf Hanefeld, et al.
Diabetes Research and Clinical Practice|May 22, 2024
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trialSilvio E Inzucchi, Christoph Wanner, David Fitchett, et al.
Journal of the American College of Cardiology|June 11, 2021
Implications of Biomarker Discordance After Coronary Artery Revascularization: The EXCEL TrialBjörn Redfors, John Gregson, Ori Ben-Yehuda, et al.
Journal of the American College of Cardiology|February 15, 2015
Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trialsGennaro Giustino, Usman Baber, Samantha Sartori, et al.
JACC. Heart Failure|November 3, 2022
Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTsJoão Pedro Ferreira, Bertram Pitt, John J V McMurray, et al.
Annals of Internal Medicine|October 4, 2017
Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort StudyÒscar Miró, Xavier Rossello, Víctor Gil, et al.
The New England Journal of Medicine|June 7, 2007
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysisPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Journal of Cardiac Failure|April 21, 2025
NSAIDs Use, Kidney Outcomes and the Effect of Empagliflozin: An Analysis from EMPEROR-PreservedJoão Pedro Ferreira, Faiez Zannad, Francisco Vasques-Nóvoa, et al.
Pageof 35

Showing results (91-100 of 349) with videos related to

Sort By:
Pageof 35
Journal of the American College of Cardiology|January 21, 2017
Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular StudiesMarkus C Elze, John Gregson, Usman Baber, et al.
European Journal of Heart Failure|March 5, 2024
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysisJoão Pedro Ferreira, Faiez Zannad, Milton Packer, et al.
Cardiovascular Diabetology|April 26, 2008
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)Michel Komajda, Paula Curtis, Markolf Hanefeld, et al.
Diabetes Research and Clinical Practice|May 22, 2024
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trialSilvio E Inzucchi, Christoph Wanner, David Fitchett, et al.
Journal of the American College of Cardiology|June 11, 2021
Implications of Biomarker Discordance After Coronary Artery Revascularization: The EXCEL TrialBjörn Redfors, John Gregson, Ori Ben-Yehuda, et al.
Journal of the American College of Cardiology|February 15, 2015
Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trialsGennaro Giustino, Usman Baber, Samantha Sartori, et al.
JACC. Heart Failure|November 3, 2022
Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTsJoão Pedro Ferreira, Bertram Pitt, John J V McMurray, et al.
Annals of Internal Medicine|October 4, 2017
Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort StudyÒscar Miró, Xavier Rossello, Víctor Gil, et al.
The New England Journal of Medicine|June 7, 2007
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysisPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Journal of Cardiac Failure|April 21, 2025
NSAIDs Use, Kidney Outcomes and the Effect of Empagliflozin: An Analysis from EMPEROR-PreservedJoão Pedro Ferreira, Faiez Zannad, Francisco Vasques-Nóvoa, et al.
Pageof 35